Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Century Therapeutics (IPSC) Income from Continuing Operations (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Income from Continuing Operations for 4 consecutive years, with 19239000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 121.69% to 19239000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 9642000.0 through Dec 2025, down 439.56% year-over-year, with the annual reading at 9653000.0 for FY2025, 440.78% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 19239000.0 at Century Therapeutics, up from 34422000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 88708000.0 in Q4 2024, with the low at 39398000.0 in Q4 2023.
  • Average Income from Continuing Operations over 4 years is 17438812.5, with a median of 31241000.0 recorded in 2023.
  • Peak annual rise in Income from Continuing Operations hit 372.82% in 2025, while the deepest fall reached 121.69% in 2025.
  • Over 4 years, Income from Continuing Operations stood at 31677000.0 in 2022, then decreased by 24.37% to 39398000.0 in 2023, then surged by 325.16% to 88708000.0 in 2024, then tumbled by 121.69% to 19239000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 19239000.0, 34422000.0, and 32541000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.